Form 4: Mirum Pharmaceuticals Executive Sells Shares

Jolanda Howe, SVP Global Controller at Mirum Pharmaceuticals, reported a sale of 2,721 common stock shares on July 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jolanda Howe, Senior Vice President, Global Controller of Mirum Pharmaceuticals, Inc., executed a transaction involving company stock.
• The transaction, which occurred on July 1, 2026, involved the sale of 2,721 shares of common stock.
• This sale was conducted under a Rule 10b5-1 trading plan, which was adopted by Ms. Howe on March 18, 2026.
• Following the transaction, Ms. Howe beneficially owns 3,114 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider transaction executed under a pre-established plan, without immediate implications for the company's fundamental performance.

Negatives

• An executive sold a portion of their holdings in the company.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a pre-planned sale, often used by executives to diversify holdings or meet financial obligations without appearing to trade on material non-public information.

Stakeholder Impact

• Shareholders may note the sale as a reduction in insider ownership, though the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Jolanda Howe, Beneficial Ownership